Browse hierarchy: [Microbiology (MI)](/submissions/MI) → [Subpart D — Serological Reagents](/submissions/MI/subpart-d%E2%80%94serological-reagents) → [21 CFR 866.3520](/submissions/MI/subpart-d%E2%80%94serological-reagents/866.3520) → GRJ — Antigen, Cf, (Including Cf Control), Rubeola

# GRJ · Antigen, Cf, (Including Cf Control), Rubeola

_Microbiology · 21 CFR 866.3520 · Class 1_

**Canonical URL:** https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/GRJ

## Overview

- **Product Code:** GRJ
- **Device Name:** Antigen, Cf, (Including Cf Control), Rubeola
- **Regulation:** [21 CFR 866.3520](/submissions/MI/subpart-d%E2%80%94serological-reagents/866.3520)
- **Device Class:** 1
- **Review Panel:** [Microbiology](/submissions/MI)

## Identification

Rubeola (measles) virus serological reagents are devices that consist of antigens and antisera used in serological tests to identify antibodies to rubeola virus in serum. The identification aids in the diagnosis of measles and provides epidemiological information on the disease. Measles is an acute, highly infectious disease of the respiratory and reticuloendothelial tissues, particularly in children, characterized by a confluent and blotchy rash.

## Classification Rationale

Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9.

## Recent Cleared Devices (2 of 2)

| Record | Device Name | Applicant | Decision Date | Decision |
| --- | --- | --- | --- | --- |
| [K843662](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/GRJ/K843662.md) | MEASLES VIRUS RUBEOLA | Institute Virion , Ltd. | Sep 26, 1985 | SESE |
| [K802932](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/GRJ/K802932.md) | MEASLES VIRUS & CONTROLS | Orion Diagnostica, Inc. | Dec 31, 1980 | SESE |

## Top Applicants

- Institute Virion , Ltd. — 1 clearance
- Orion Diagnostica, Inc. — 1 clearance

---

**Source:** [https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/GRJ](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/GRJ)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com